Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Wordsworth

Showing results (51-60 of 141) with videos related to

Pageof 15
Sort By:
Pharmacoeconomics|August 2, 2017
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness AnalysisJames Buchanan, Sarah Wordsworth, Ruth Clifford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation ModelingDeborah A Marshall, Luiza R Grazziotin, Dean A Regier, et al.
BMC Medicine|June 22, 2019
Optimising trial designs to identify appropriate antibiotic treatment durationsKoen B Pouwels, Mo Yin, Christopher C Butler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough SolutionsKathryn A Phillips, Patricia A Deverka, Deborah A Marshall, et al.
Health Economics|February 23, 2022
Eliciting risk preferences that predict risky health behavior: A comparison of two approachesMurong Yang, Laurence S J Roope, James Buchanan, et al.
Ophthalmology|May 15, 2012
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Usha Chakravarthy, Simon P Harding, et al.
The New England Journal of Medicine|March 12, 2015
Liberal or restrictive transfusion after cardiac surgeryGavin J Murphy, Katie Pike, Chris A Rogers, et al.
BMJ (Clinical Research Ed.)|November 9, 2022
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort studySarah E W Briggs, Philip Law, James E East, et al.
Applied Health Economics and Health Policy|March 27, 2013
Resource-use measurement based on patient recall: issues and challenges for economic evaluationJoanna C Thorn, Joanna Coast, David Cohen, et al.
Personalized Medicine|September 25, 2023
Cost-effectiveness of alternative <i>NTRK</i> testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countriesHeleen Vellekoop, Simone Huygens, Matthijs Versteegh, et al.
Pageof 15

Showing results (51-60 of 141) with videos related to

Sort By:
Pageof 15
Pharmacoeconomics|August 2, 2017
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness AnalysisJames Buchanan, Sarah Wordsworth, Ruth Clifford, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation ModelingDeborah A Marshall, Luiza R Grazziotin, Dean A Regier, et al.
BMC Medicine|June 22, 2019
Optimising trial designs to identify appropriate antibiotic treatment durationsKoen B Pouwels, Mo Yin, Christopher C Butler, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough SolutionsKathryn A Phillips, Patricia A Deverka, Deborah A Marshall, et al.
Health Economics|February 23, 2022
Eliciting risk preferences that predict risky health behavior: A comparison of two approachesMurong Yang, Laurence S J Roope, James Buchanan, et al.
Ophthalmology|May 15, 2012
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Usha Chakravarthy, Simon P Harding, et al.
The New England Journal of Medicine|March 12, 2015
Liberal or restrictive transfusion after cardiac surgeryGavin J Murphy, Katie Pike, Chris A Rogers, et al.
BMJ (Clinical Research Ed.)|November 9, 2022
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort studySarah E W Briggs, Philip Law, James E East, et al.
Applied Health Economics and Health Policy|March 27, 2013
Resource-use measurement based on patient recall: issues and challenges for economic evaluationJoanna C Thorn, Joanna Coast, David Cohen, et al.
Personalized Medicine|September 25, 2023
Cost-effectiveness of alternative <i>NTRK</i> testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countriesHeleen Vellekoop, Simone Huygens, Matthijs Versteegh, et al.
Pageof 15